|
|
|
| Effect of Alteplase on ultra early stage for clinical outcome of patients with cerebral infarction |
| LI Hongfei XU Dongjuan ZHANG Weiqiang GUO Xiang |
| Department of Neurology, Dongyang People's Hospital, Zhejiang Province, Dongyang 322100, China |
|
|
|
Abstract Objective To investigate the effect of Alteplase on ultra early stage for clinical outcome of patients with cerebral infarction. Methods From October 2015 to December 2016, in Dongyang People's Hospital, 120 cerebral infarction patients were selected, they were divided into the observation group (60 cases) and control group (60 cases) by random number table, the control group was given routine treatment, the observation group was given Alteplase on ultra early stage based on the control group, two groups were treated for 14 d. Neuron specific enolase (NSE), central nerve specific protein (S100β) and inflammatory factor, neurological function, life ability and adverse reaction of two groups were compared. Results After treatment, the NSE and S100 in observation group were lower than those in control group, IL-6, TNF-a, CRP was lower than those in control group, the differences were statistically significant (P < 0.05). The MBI score in observation group was higher than that in control group, the NIHSS score was lower than that in control group, the differences were statistically significant (P < 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05). Conclusion Alteplase on ultra early stage can significantly reduce inflammatory factors, NSE and S100β level of patients with cerebral infarction, improve neurological function and life ability, and less adverse reactions, it is a safe and effective treatment method.
|
|
|
|
|
|
[1] Gounis MG，Nogueira RG，Mehra M，et al. A thromboembolic model for the efficacy and safety evaluation of combined mechanical and pharmacologic revascularization strategies [J]. J Neurointerv Surg，2013，5（Suppl１）：85-86.
[2] Jauch EC，Saver JL，Adams HP，et al. Guidelines for the early management of patients with acute ischemic stroke：a guideline for health-care professionals from the American Heart Association/American Stroke Association [J]. Stroke，2013，44（3）：870-947.
[3] Sung SF，Chen CH，Chen YW，et al. Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis:stroke territory as a potential pitfall [J]. J Neurol Sci，2013， 335（1- 2）：96-100.
[4] Dorňák，Král M，Hazlinger M，et al. Posterior vs.anterior circulation infarction:demography，outcomes，and frequency of hemorrhage after thrombolysis [J]. Int J Stroke，2015，10（8）：1224-1228.
[5] 胡继川，龚雪琴.阿替普酶超早期静脉溶栓治疗急性脑梗死20例[J].中国老年学杂志，2012，32（9）：1932-1933.
[6] 张佩兰，张辰昊，陈岩，等.阿替普酶静脉溶栓治疗急性缺血性卒中临床研究[J].中国现代神经疾病杂志，2013， 13（4）：291-296 .
[7] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[8] 滕旭升，程谦涛.rt-PA静脉溶栓治疗急性缺血性脑卒中的临床疗效观察[J].中国现代医生，2013，51（36）：54-57，60.
[9] Dunning K. National Institute of health stroke scale [J]. Encyclopedia Clin Neuropsychol，2011，9（1）：1714-1715.
[10] 李小峰，陈敏.改良Barthel指数评定量表的设计与应用[J].护理研究，2015，10（13）：1657-1658.
[11] 李兰红，王晋芳.阿司匹林联合氯吡格雷治疗急性进展性脑梗死的疗效观察[J].中西医结合心脑血管病杂志，2016，14（16）：1926-1927.
[12] 王小兰.阿替普酶治疗急性脑梗死的临床疗效探析[J].齐齐哈尔医学院学报，2013，34（11）：1578-1579 .
[14] 程超婵，涂汉明，应爱娟，等.阿替普酶联合丁苯酞对急性脑梗死的临床疗效及作用机制研究[J].中国临床药理学杂志，2015，31（23）：2293-2296.
[15] Wardlaw JM，Murray V，Berge E，et al. Thrombolysis for acute ischaemic stroke [J]. Cochrane Database Syst Rev，2014，7（29）：CD000213.
[16] 程超婵，潘君枝.阿替普酶治疗老年急性脑梗死的效果及对血清神经特异性烯醇化酶、S100p蛋白的影响[J].中国老年学杂志，2016，36（6 ）：2632-2634.
[17] Sarraj A，Medrek S，,Albright K，et al. Posterior circulation stroke is associated with prolonged door-to-needle time [J]. Int J Stroke，2015，10（5）：672-678.
[18] 孙永兴，刘玉祥，张凝远.急性缺血性脑卒中阿替普酶静脉溶栓治疗28例临床分析[J].重庆医学，2015，44（15）：2120-2121.
[19] 戴德孟，马维斌.阿替普酶治疗急性脑梗死的疗效及对患者血清炎性因子的影响[J].中国老年学杂志，2012， 36（1）：67-68.
[20] Tosta ED，Rebello LC，Almeida SS，et al. Treatment of ischemic stroke with r-tPA：implementation challenges in a tertiary hospital in Brazil [J]. Arq Neuropsiquiatr，2014， 72（5）：368-372.
[21] 史宝和，陈晓虹，李成洋，等.阿替普酶治疗急性脑梗死的疗效和安全性研究[J].实用药物与临床，2012，15（10）：635-636.
[22] 佟旭，郑华光，曹亦宾，等.阿替普酶静脉溶栓治疗前、后循环卒中的安全性和有效性的meta分析[J].中风与神经疾病杂志，2016，33（9）：802-807.
[23] 谢江文，吕国菊，郑珍婕，等.不同年龄对阿替普酶静脉溶栓治疗急性脑梗死的临床疗效和预后的影响[J].中国临床药理学杂志，2016，32（6）：486-488. |
|
|
|
